first trial in the United States to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinsons

[Farooqji]

This is a big step for the stem cell field – to finally test a truly “off-the-shelf” dopamine neuron product in human PD patients

bluerocktx.com/news/blueroc...

[Farooqji]

Lead Program in Parkinson’s Disease

BlueRock’s founders have pioneered the derivation of dopaminergic neurons that have demonstrated robust preclinical data to restore motor function and increased dopamine release as they mature. Our lead program is an authentic cellular therapy candidate to treat Parkinson’s disease, which we expect to advance into clinical development, having already established preclinical proof of concept.

Why Parkinson’s Disease?

Parkinson’s Disease is the second most common neurodegenerative disorder, affecting an estimated 1.3 million people in the U.S. and greater than 7.5 million globally. It is a chronic and progressive disease that current treatments do not adequately address. The primary and most debilitating symptom is a progressive loss of motor control.

Using our authentic dopaminergic neurons as therapy, we aim to re-innervate the human brain and reverse degenerative disease, potentially restoring motor function to the millions of patients suffering from Parkinson’s.

bluerocktx.com/pipeline/